{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:28:42Z","timestamp":1791829722481,"version":"4.3.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Venous thromboembolism (VTE) is a serious life-threatening complication among patients with cancer. This systematic review and meta-analysis aimed to quantify the proportion of VTE across different cancer types, stages, and study settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive literature review was conducted to identify observational studies reporting VTE events in cancer patients. Studies were categorized into population-based and hospital-based settings to compare VTE prevalence. Cancer types were classified by anatomical origin, and cancer stages (Stage I\u2013IV). Meta-analytic techniques were applied using R software, and pooled VTE proportions with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the I\u00b2 statistic, and forest plots were generated for visualization. Sensitivity analyses were conducted to evaluate the robustness of findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>The analysis included 14 studies, out of which hospital-based studies reported a significantly higher VTE proportion (4.1%) compared to population-based studies (2.9%) (<jats:italic>p<\/jats:italic> &amp;lt;.001, \u03c7\u00b2 = 1452.219). Among cancer types, gastrointestinal malignancies had the highest pooled VTE proportions, followed by hematologic and urogenital cancers. In hospital-based cohorts, lung and breast cancers showed particularly high VTE burdens. VTE risk increased with advancing cancer stage, with the highest proportions observed in Stage III and IV cancers. This meta-analysis demonstrates substantial variation in VTE risk based on study setting, cancer type, and stage. The findings underscore the need for nuanced, type- and stage-specific VTE risk assessment models to guide effective prophylaxis and clinical decision-making in oncology practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024616005<\/jats:uri>, identifier CRD42024616005.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1619554","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:11:10Z","timestamp":1759205470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies"],"prefix":"10.3389","volume":"15","author":[{"given":"Vikram","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peteneinuo","family":"Rulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e072715","DOI":"10.1136\/bmj-2022-072715","article-title":"Prevention of venous thromboembolism in patients with cancer","volume":"381","author":"Guntupalli","year":"2023","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B3","first-page":"188","article-title":"De l\u2019Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general","volume":"1","author":"Bouillaud","year":"1823","journal-title":"Arch Gen Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0169","article-title":"Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting","volume":"108","author":"Kahn","year":"2012","journal-title":"Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0064","article-title":"Risk assessment and prophylaxis for VTE in cancer patients","volume":"9","author":"Khorana","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial thromboembolism in cancer patients: a Danish population\u2013based cohort study","volume":"3","author":"Mulder","year":"2021","journal-title":"Cardiooncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971\u20132011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100739","article-title":"Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study","volume":"34","author":"S\u00f8rensen","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15250","article-title":"Pulmonary embolism at autopsy in cancer patients","volume":"19","author":"Gimbel","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients\u2019 quality of life","volume":"21","author":"Lloyd","year":"2018","journal-title":"Value Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"B18","volume-title":"TNM classification of Malignant tumours","author":"Sobin","year":"2011"},{"key":"B19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer\u2013a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15527","article-title":"Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer-VTE Registry)","volume":"113","author":"Ikeda","year":"2022","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14911","article-title":"Risk factors for venous thromboembolism in patients with small cell lung cancer","volume":"41","author":"Dimakakos","year":"2021","journal-title":"Anticancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5144\/1658-3876.2010.191","article-title":"Cancer-related venous thromboembolism: insight into underestimated risk factors","volume":"3","author":"Al Diab","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.190827","article-title":"High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study","volume":"29","author":"Vormittag","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival","volume":"170","author":"Saadeh","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31811ea275","article-title":"High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients","volume":"2","author":"Tagalakis","year":"2007","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055485","article-title":"Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden","volume":"12","author":"Balabanova","year":"2022","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1138","article-title":"Venous thromboembolism and cancer risk among elderly adults in the United States","volume":"23","author":"Marks","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70038-3","article-title":"Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"11","author":"Van Hemelrijck","year":"2010","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.182410","article-title":"Methodology series module 3: Cross-sectional studies","volume":"61","author":"Setia","year":"2016","journal-title":"Indian J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer\u2014a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp354","article-title":"Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial","volume":"21","author":"Mandala","year":"2010","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.09.013","article-title":"High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients","volume":"42","author":"Blom","year":"2006","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MBC.0b013e328341f030","article-title":"Risk of recurrent venous thromboembolism according to Malignancy characteristics in patients with cancer-associated thrombosis: a systematic review","volume":"22","author":"Louzada","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis. Blood","volume":"130","author":"Hisada","year":"2017","journal-title":"J Am Soc Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PloS Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0510-x","article-title":"The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues","volume":"12","author":"Campello","year":"2019","journal-title":"Br J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological Malignancies","volume":"14","author":"Colombo","year":"2014","journal-title":"Clin lymphoma myeloma leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.07.013","article-title":"Role of the coagulation system in genitourinary cancers: review","volume":"3","author":"John","year":"2017","journal-title":"Clin genitourinary cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4103\/jpcs.jpcs_31_17","article-title":"Number needed to treat","volume":"3","author":"Biswas","year":"2017","journal-title":"J Pract Cardiovasc Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1619554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:11:13Z","timestamp":1759205473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1619554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":42,"alternative-id":["10.3389\/fonc.2025.1619554"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1619554","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1619554"}}